Physician profile
Mathew Good
NPI 1346469582
$3,203.05
in general payments reported to CMS, 2019-2025
24 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $107 · 2021: $1,051 · 2022: $404 · 2023: $289 · 2024: $286 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,267.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $837.50 | 2021 | |
| Abiomed | $389.81 | 2024-2025 | Impella |
| Pfizer INC. | $289.22 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $286.76 | 2021-2025 | |
| Heartflow, INC. | $268.25 | 2019-2021 | |
| Amgen INC. | $126.36 | 2019-2025 | Repatha, Repatha |
| Regeneron Pharmaceuticals, INC. | $125.11 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.87 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $101.55 | 2019-2024 | Xarelto |
| Inspire Medical Systems, INC. | $97.62 | 2024-2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $92.07 | 2024-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.70 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $90.17 | 2022-2025 | Verquvo, Capvaxive |
| Angiodynamics, INC. | $81.12 | 2025 | Alphavac |
| Bayer Healthcare Pharmaceuticals INC. | $32.04 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $31.60 | 2019 | |
| Abbott Laboratories | $25.00 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.36 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $19.31 | 2023 | Farxiga |
| Daiichi Sankyo INC. | $18.99 | 2023 | Injectafer |
| Surmodics, INC. | $15.86 | 2023 | Pounce Thrombectomy |
| Actelion Pharmaceuticals US, INC. | $14.16 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Good listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.